Food & Beverages Food for a growing world

Similar documents
DuPont Nutrition & Health Craig Binetti, President

Food Specialties Patrick Niels President DSM Food Specialties ROYAL DSM HEALTH NUTRITION MATERIALS

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS

DSM Capital Markets Day 2018

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Business Contributions to Setting New Research Agendas: Business Platform for Nutrition Research (BPNR)

Harm de Wildt MD TNI

Putting ALK on the right growth trajectory

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

A world leader in allergy immunotherapy

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

The acquisition of Fortitech

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

FRUIT STARCH SUGAR. AGRANA Beteiligungs-AG. The natural upgrade. Corporate presentation

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Value growth in Human Nutrition & Health

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Continued value growth

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Whole Grain and High Fiber - Global Market Outlook ( )

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

Slide 1. Investor presentation. London 5 February 2019

Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA

27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009

2015 Investor Conference

Expert support to create cost-effective dairy taste and texture

January 30, 2018 Dow Wilson President and Chief Executive Officer

GELATIN & AKIOLIS. Because every bio-molecule counts. Pol Deturck EVP Chemicals & Organic Specialties

Corporate Presentation

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011

Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018

For personal use only

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Health & Nutrition Driving Grains Innovation Australian Grains Industry Conference 29 July 2014

Driving Profitable Growth

Efforts start to pay off in the fourth quarter

Presentation to 2019 JP Morgan Healthcare Conference

William Blair 30 th Annual Growth Stock Conference

Slide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010

TELECONFERENCE FY February 2015

Universal Biosensors, Inc.

NASDAQ: ELGX December Innovation that Empowers

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015

Photocure ASA Executing the Strategy

BUILDING BUSINESS THROUGH SYNERGY

Building a Global Neurotoxin Franchise

First and foremost we have the world s largest privately funded biomedical research group investing about $8 billion in 2008.

TELECONFERENCE Q November 2015

Global Nutraceuticals Market

William Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation

Nordea investor meeting. June 18 th, 2018 Kristian Villumsen, EVP Chronic Care

Oral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development

OPPORTUNITIES FOR OMEGA-3 PRODUCTS

Cowen Investor Conference March confidently live life with ease

For personal use only

Photocure ASA Executing the Strategy

Connect with consumers for life. Introducing new MEG-3 Ultra and life sdha Ultra

Consumer Wellness in India Growth Ahead

Keeping product information relevant in response to consumer demand: from what s not in your food to what is

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011

Gavi s private sector engagement approach

Probiotics Market Size, Share, Analysis, Growth, Trends, Outlook and Forecasts to 2024 Hexa Research

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

Global Market for Infant Formula and Dairy Ingredients

(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health. December 2018

Global Stevia Extracts Market Analysis By Type (Dried, Leaves, Powder, Liquid), Application, Region, Country: Opportunities and Forecast ( )

Karel Stoschek Director Infant Nutrition. Infant Nutrition

Positioned for Growth

A GLOBAL LEADER IN PERSONALIZED NUTRITION

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

BALCHEM CORPORATION. Q Investor Relations Presentation

Coloplast A/S. Investor presentation 1H 2005/06

34 th Annual J.P. Morgan Healthcare Conference

Südzucker Group Capital market forum Rhine Neckar

TELECONFERENCE Q August 2015

The US Meal Kit Market: Size, Trends & Forecasts ( ) August 2017

The Savvy Sales & Marketer s Field Guide to. Fats & Oils. Solutions for Better-for-You Products! 5 th Edition

Solvay expands its specialty polymers offerings with Ryton PPS acquisition

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region

The value of pre-competitive food research FHI s Story

Human Sundhed som konkurrenceparameter Arla Foods Ingredients GUDP

High Oleic Soybean Oil Panel. National Institute of Oilseed Products March 17, 2015

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research

Cochlear Limited 2017 Annual General Meeting Chairman s Address

Myriad Genetics Corporate Presentation 06/13/2018

Whole Grains Go Global

Expert support to create cost-effective dairy taste and texture

MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders

ProSid TM. Making a difference in fighting mould problems. Feed additives that give key benefits

Investor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications

Transcription:

Food & Beverages Food for a growing world Rasmus von Gottberg, Vice President F&B Marketing, Novozymes Christel Thea Jørgensen, Vice President R&D, Novozymes Jeremy Bentham, Go to Market Director, Cargill Food Ingredients & Systems Europe, Middle East, Africa

Forward-Looking Statements This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limited to, "believe," "anticipate," "expect," "estimate," "intend," "plan," "project," "could," "may," "might" and other words of similar meaning. Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to differ materially from expectations, both positively and negatively. The risks and uncertainties may, among other things, include unexpected developments in i) the ability to develop and market new products; ii) the demand for Novozymes products, market-driven price decreases, industry consolidation, and launches of competing products or disruptive technologies in Novozymes core areas; iii) the ability to protect and enforce the company s intellectual property rights; iv) significant litigation or breaches of contract; v) the materialization of the company s growth platforms, notably the opportunity for marketing biomass conversion technologies or the development of microbial solutions for broad-acre crops; vi) the political conditions, such as acceptance of enzymes produced by genetically modified organisms; vii) the global economic and capital market conditions, including, but not limited to, currency exchange rates (USD/DKK and EUR/DKK in particular, but not exclusively), interest rates and inflation; viii) significant price decreases on input and materials that compete with Novozymes biological solutions. The company undertakes no obligation to update any forward-looking statements as a result of future developments or new information. 2

Session outline Novozymes position and value proposition in Food & Beverages Views from Cargill: creating sustainable business Novozymes innovation priorities 3

Food & Beverages enzymes summary The largest category in the enzyme world A small fraction of food ingredients and processing aids A global industry with many applications DKK ~15bn DKK ~9bn Enzymes for Detergents Biofuels Feed Technical applications Enzymes Food & Beverages DKK +300bn DKK ~9bn Food Ingredients Flavors & colors Processing ingredients Preservatives Specialty proteins Other ingredients Starch, oils & fats Beverages Food & Nutrition Baking Source: Novozymes own estimates, Leatherhead, expert interviews, GXC, Freedonia, Euromonitor Source: Novozymes own estimates 4

Novozymes is the global leader in the Food & Beverages enzyme market Most fragmented and diverse market for Novozymes F&B enzyme market Broad portfolio of 300+ products across applications Top 5 customers make up ~20% of sales vs. 31% for the Group Distributors important for global reach (~30% of sales) DSM, DuPont, Others + Captive Source: Novozymes own estimates. Strong market position and robust growth driver Novozymes is #1 in all the main markets where it plays (all main markets except cheese coagulants) 6% sales CAGR since IPO 26% of Group sales today Fragmented industry structure and industry profile make for slower ramp-up of new products, but long lifetime Novozymes sales, DKKm 2000-2014 3000 2000 1000 0 +6% 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 5

We cover a broad set of end markets and applications We operate in different parts of the value chain. Revenue-wise, the two parts are comparable Processing of Ag inputs A global business with global solutions Starch processing Characteristics: Starch processing main business Fewer product categories DuPont main competitor Food products Product-driven for developed markets Baking Characteristics: Baking main market Many products to many end customers Competition more Fragmented global dispersed and local Brewing Juice & wine Beverage alcohol Oils & fats processing customer base ~60% direct sales ~60% emerging markets Infant food Flavor enhancement Low lactose Acrylamide reduction ~80% direct sales ~30% emerging markets 6

Bioinnovation and Novozymes can have a greater impact on consumers and society Four defining trends set the scope for future growth More with less Health Emerging markets industrialization Consumers wanting more natural foods and define innovation opportunities for the future Unlock new substrate streams Enhance productivity offering in existing markets Freshkeeping Remove unwanted compounds 7

R&D investments to drive impact and increase partnering within updated focus areas More R&D resources for near-market impact & long-term opportunities in partnership Innovation focus Investment Baking Food & Nutrition Oils & Fats Starch Beverages Raw material flexibility Fresh & tasty Healthy & safe Productivity & yield Nearmarket Incremental innovation Big bets New business incubation 9

Focusing on near-market opportunities and big bets requires strenghtening of two different skillsets Partnerships a must for big bets - Leverage partner competencies from other industries - Develop model for stronger partner engagement - Build innovation relationships with end customers Drive near-market opportunities - In-field application development - Closer interaction with customers - Manning-up in emerging markets - Use of local raw materials Benefit from changes in innovation pipeline management - Portfolio management to reduce incremental innovation with limited commercial opportunity 10

Deeper and broader in a platform and with partners Example: Deeper and broader in Oils & Fats Situation: Smaller business today for oil processing Future Through partnerships: Develop application and process understanding to drive development, building value for partner and enabling a broader shift to biological processing of oil seeds Unlock other oil-rich substrate streams Example: Deeper and broader with Cargill Situation: Longstanding relationship in starch, but limited experience within other business areas Future: Enhance innovation partnership to allow for broader strategic scope of collaboration across verticals. E.g. Oils & Fats processing 11

Conclusion A good longstanding business for Novozymes 4 defining trends shape opportunity to create more impact: More with less Health Emerging markets industrialization Consumers wanting more natural foods Partnering for impact: Unlock new substrate streams Enhance productivity offering in existing markets Freshkeeping Remove unwanted compounds 12